1740 related articles for article (PubMed ID: 25201530)
21. TMPRSS2-ERG Fusion Promotes Recruitment of Regulatory T cells and Tumor Growth in Prostate Cancer.
Shan L; Ji T; Su X; Shao Q; Du T; Zhang S
Am J Med Sci; 2018 Jul; 356(1):72-78. PubMed ID: 30049331
[TBL] [Abstract][Full Text] [Related]
22. SPOP mutations in prostate cancer across demographically diverse patient cohorts.
Blattner M; Lee DJ; O'Reilly C; Park K; MacDonald TY; Khani F; Turner KR; Chiu YL; Wild PJ; Dolgalev I; Heguy A; Sboner A; Ramazangolu S; Hieronymus H; Sawyers C; Tewari AK; Moch H; Yoon GS; Known YC; Andrén O; Fall K; Demichelis F; Mosquera JM; Robinson BD; Barbieri CE; Rubin MA
Neoplasia; 2014 Jan; 16(1):14-20. PubMed ID: 24563616
[TBL] [Abstract][Full Text] [Related]
23. CHD1 and SPOP synergistically protect prostate epithelial cells from DNA damage.
Zhu Y; Wen J; Huang G; Mittlesteadt J; Wen X; Lu X
Prostate; 2021 Jan; 81(1):81-88. PubMed ID: 33022763
[TBL] [Abstract][Full Text] [Related]
24. Viability Analysis and High-Content Live-Cell Imaging for Drug Testing in Prostate Cancer Xenograft-Derived Organoids.
Van Hemelryk A; Erkens-Schulze S; Lim L; de Ridder CMA; Stuurman DC; Jenster GW; van Royen ME; van Weerden WM
Cells; 2023 May; 12(10):. PubMed ID: 37408211
[TBL] [Abstract][Full Text] [Related]
25. Morphological features of TMPRSS2-ERG gene fusion prostate cancer.
Mosquera JM; Perner S; Demichelis F; Kim R; Hofer MD; Mertz KD; Paris PL; Simko J; Collins C; Bismar TA; Chinnaiyan AM; Rubin MA
J Pathol; 2007 May; 212(1):91-101. PubMed ID: 17385188
[TBL] [Abstract][Full Text] [Related]
26. Prostate Organoid Cultures as Tools to Translate Genotypes and Mutational Profiles to Pharmacological Responses.
Pappas KJ; Choi D; Sawyers CL; Karthaus WR
J Vis Exp; 2019 Oct; (152):. PubMed ID: 31710046
[TBL] [Abstract][Full Text] [Related]
27. A novel four-color fluorescence in situ hybridization assay for the detection of TMPRSS2 and ERG rearrangements in prostate cancer.
Qu X; Randhawa G; Friedman C; O'Hara-Larrivee S; Kroeger K; Dumpit R; True L; Vakar-Lopez F; Porter C; Vessella R; Nelson P; Fang M
Cancer Genet; 2013; 206(1-2):1-11. PubMed ID: 23352841
[TBL] [Abstract][Full Text] [Related]
28. ERG and CHD1 heterogeneity in prostate cancer: use of confocal microscopy in assessment of microscopic foci.
Tereshchenko IV; Zhong H; Chekmareva MA; Kane-Goldsmith N; Santanam U; Petrosky W; Stein MN; Ganesan S; Singer EA; Moore D; Tischfield JA; DiPaola RS
Prostate; 2014 Nov; 74(15):1551-9. PubMed ID: 25175909
[TBL] [Abstract][Full Text] [Related]
29. A Three-Dimensional Organoid Culture System Derived from Human Glioblastomas Recapitulates the Hypoxic Gradients and Cancer Stem Cell Heterogeneity of Tumors Found In Vivo.
Hubert CG; Rivera M; Spangler LC; Wu Q; Mack SC; Prager BC; Couce M; McLendon RE; Sloan AE; Rich JN
Cancer Res; 2016 Apr; 76(8):2465-77. PubMed ID: 26896279
[TBL] [Abstract][Full Text] [Related]
30. Organoid Cultures as Preclinical Models of Non-Small Cell Lung Cancer.
Shi R; Radulovich N; Ng C; Liu N; Notsuda H; Cabanero M; Martins-Filho SN; Raghavan V; Li Q; Mer AS; Rosen JC; Li M; Wang YH; Tamblyn L; Pham NA; Haibe-Kains B; Liu G; Moghal N; Tsao MS
Clin Cancer Res; 2020 Mar; 26(5):1162-1174. PubMed ID: 31694835
[TBL] [Abstract][Full Text] [Related]
31. Phase II study of cytarabine in men with docetaxel-refractory, castration-resistant prostate cancer with evaluation of TMPRSS2-ERG and SPINK1 as serum biomarkers.
Dhani NC; Emmenegger U; Adams L; Jongstra J; Tannock IF; Sridhar SS; Knox JJ; Day JR; Groskopf J; Joshua AM
BJU Int; 2012 Sep; 110(6):840-5. PubMed ID: 22313860
[TBL] [Abstract][Full Text] [Related]
32. [Progress in prostate cancer study: 3D cell culture enables the ex vivo reproduction of tumor characteristics].
Tostivint V; Racaud-Sultan C; Roumiguié M; Soulié M; Gamé X; Beauval JB
Presse Med; 2017 Oct; 46(10):954-965. PubMed ID: 28967525
[TBL] [Abstract][Full Text] [Related]
33. TabBO: a model reflecting common molecular features of androgen-independent prostate cancer.
Navone NM; Rodriquez-Vargas MC; Benedict WF; Troncoso P; McDonnell TJ; Zhou JH; Luthra R; Logothetis CJ
Clin Cancer Res; 2000 Mar; 6(3):1190-7. PubMed ID: 10741751
[TBL] [Abstract][Full Text] [Related]
34. Circulating Tumor DNA Abundance and Potential Utility in De Novo Metastatic Prostate Cancer.
Vandekerkhove G; Struss WJ; Annala M; Kallio HML; Khalaf D; Warner EW; Herberts C; Ritch E; Beja K; Loktionova Y; Hurtado-Coll A; Fazli L; So A; Black PC; Nykter M; Tammela T; Chi KN; Gleave ME; Wyatt AW
Eur Urol; 2019 Apr; 75(4):667-675. PubMed ID: 30638634
[TBL] [Abstract][Full Text] [Related]
35. SPOP Promotes Ubiquitination and Degradation of the ERG Oncoprotein to Suppress Prostate Cancer Progression.
Gan W; Dai X; Lunardi A; Li Z; Inuzuka H; Liu P; Varmeh S; Zhang J; Cheng L; Sun Y; Asara JM; Beck AH; Huang J; Pandolfi PP; Wei W
Mol Cell; 2015 Sep; 59(6):917-30. PubMed ID: 26344095
[TBL] [Abstract][Full Text] [Related]
36. A suspension technique for efficient large-scale cancer organoid culturing and perturbation screens.
Price S; Bhosle S; Gonçalves E; Li X; McClurg DP; Barthorpe S; Beck A; Hall C; Lightfoot H; Farrow L; Ansari R; Jackson DA; Allen L; Roberts K; Beaver C; Francies HE; Garnett MJ
Sci Rep; 2022 Apr; 12(1):5571. PubMed ID: 35368031
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of urinary prostate cancer antigen-3 (PCA3) and TMPRSS2-ERG score changes when starting androgen-deprivation therapy with triptorelin 6-month formulation in patients with locally advanced and metastatic prostate cancer.
Martínez-Piñeiro L; Schalken JA; Cabri P; Maisonobe P; de la Taille A;
BJU Int; 2014 Oct; 114(4):608-16. PubMed ID: 24806330
[TBL] [Abstract][Full Text] [Related]
38. Engineering prostate cancer in vitro: what does it take?
Buskin A; Scott E; Nelson R; Gaughan L; Robson CN; Heer R; Hepburn AC
Oncogene; 2023 Aug; 42(32):2417-2427. PubMed ID: 37438470
[TBL] [Abstract][Full Text] [Related]
39. An organoid platform for ovarian cancer captures intra- and interpatient heterogeneity.
Kopper O; de Witte CJ; Lõhmussaar K; Valle-Inclan JE; Hami N; Kester L; Balgobind AV; Korving J; Proost N; Begthel H; van Wijk LM; Revilla SA; Theeuwsen R; van de Ven M; van Roosmalen MJ; Ponsioen B; Ho VWH; Neel BG; Bosse T; Gaarenstroom KN; Vrieling H; Vreeswijk MPG; van Diest PJ; Witteveen PO; Jonges T; Bos JL; van Oudenaarden A; Zweemer RP; Snippert HJG; Kloosterman WP; Clevers H
Nat Med; 2019 May; 25(5):838-849. PubMed ID: 31011202
[TBL] [Abstract][Full Text] [Related]
40. Organoid culture systems for prostate epithelial and cancer tissue.
Drost J; Karthaus WR; Gao D; Driehuis E; Sawyers CL; Chen Y; Clevers H
Nat Protoc; 2016 Feb; 11(2):347-58. PubMed ID: 26797458
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
